Questions of the Month
For too long an enigma, lipoprotein(a) [Lp(a)] has now taken centre stage on the strength of epidemiologic and genetic studies showing that an elevated Lp(a) level is a causal risk factor for cardiovascular disease. However, there is a major obstacle to the management of high…read more »
What can we learn from the Homozygous Familial Hypercholesterolaemia International Clinical Collaboration registry?
Homozygous familial hypercholesterolaemia (HoFH) is the most severe presentation of this inherited lipid disorder, characterised by accelerated premature atherosclerotic cardiovascular disease due to the burden of extremely elevated LDL cholesterol levels from birth. Insights into management, however, are limited due to the rarity of the…read more »
Kiran Musunuru, Professor and Genetics Researcher at University of Pennsylvania, USA discusses the prospects for a one-shot “vaccination” against heart attacks, the leading cause of death worldwide. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing has evolved rapidly to allow for testing in a…read more »
Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) gives his view. Evinacumab is a remarkable therapy for individuals with homozygous familial hypercholesterolaemia (HoFH) and can result in a further 60% reduction in LDL cholesterol levels on top of aggressive lipid lowering therapy (1)….read more »
INTENSITY-HIGH: Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease The landmark PCSK9 inhibitor trials – FOURIER and ODYSSEY OUTCOMES – established the cardiovascular benefits of lowering LDL cholesterol to very…read more »